RESECTABLE NON-SMALL-CELL LUNG CANCER
Clinical trials for RESECTABLE NON-SMALL-CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RESECTABLE NON-SMALL-CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RESECTABLE NON-SMALL-CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lung cancer trial tests cocktail of new drugs against standard care
Disease control OngoingThis phase 2 study tests several new drug combinations in people with non-small-cell lung cancer. It includes three substudies: one for untreated advanced cancer, one for cancer that has progressed after prior treatment, and one for early-stage cancer that can be surgically remov…
Matched conditions: RESECTABLE NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to wipe out lung cancer before surgery
Disease control OngoingThis phase 2 trial tests whether adding an experimental immunotherapy (fianlimab) to standard immunotherapy (cemiplimab) and chemotherapy works better than the standard combo alone for people with early-stage lung cancer that can be removed by surgery. About 195 participants will…
Matched conditions: RESECTABLE NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug combo aims to shrink lung tumors before surgery
Disease control OngoingThis phase II trial is testing a new drug called AK112, alone or with chemotherapy, in people with resectable non-small cell lung cancer. The goal is to see if giving the treatment before and after surgery can help shrink tumors and prevent the cancer from coming back. The study …
Matched conditions: RESECTABLE NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Lung cancer drug combo trial pulled before it began
Disease control TerminatedThis study planned to test a targeted cancer pill (adagrasib) alone or with an immunotherapy drug (nivolumab) before surgery in people with a specific type of lung cancer (KRAS G12C mutation). The goal was to see if these drugs could eliminate all cancer cells by the time of surg…
Matched conditions: RESECTABLE NON-SMALL-CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 26, 2026 17:04 UTC